APA (7th ed.) Citation

Cen Guo, Kai H. Liao, Meng Li, I‐Ming Wang, Naveed Shaik, & Donghua Yin. (2023). PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor. Wiley.

Chicago Style (17th ed.) Citation

Cen Guo, Kai H. Liao, Meng Li, I‐Ming Wang, Naveed Shaik, and Donghua Yin. PK/PD Model‐informed Dose Selection for Oncology Phase I Expansion: Case Study Based on PF‐06939999, a PRMT5 Inhibitor. Wiley, 2023.

MLA (9th ed.) Citation

Cen Guo, et al. PK/PD Model‐informed Dose Selection for Oncology Phase I Expansion: Case Study Based on PF‐06939999, a PRMT5 Inhibitor. Wiley, 2023.